Fareston Articles
Ariad and GTx both see their share price plunge, each after updating on cancer drug clinical trials
27 May 2010
GTx/Ipsen's toremifene meets key endpoints
3 March 2008
GTx presents strong interim Ph II Acapodene data
5 March 2007
GTx' Acapodene trials get DSMB approval
12 February 2007
Ipsen nine-months sales up 8.8%
6 November 2006
Ipsen licenses GTx' SERM Acapodene in EU
18 September 2006
Toremifene shows promise in cancer prevention
23 May 2005
GTx gets exclusive US rights for Orion's toremifene
20 December 2004
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
Orion benefits from Pharmacia payment
7 November 2001
GTx to test toremifene for prevention
26 October 2001
Orion Pharma 2nd-qtr net sales up 8.1%
13 August 2001
Pharma profits well down at Orion
9 May 2001
Orion in-house drugs now 28% of turnover
23 February 2001
Overseas sales boost Orion Pharma
10 November 2000
Shire's Fareston shows equivalence to tamoxifen
25 May 2000
Asta Comes Through Tough Year, Looks To Expansion
4 March 1998
S-P Introduces Fareston In USA
4 December 1997
USA Clears Fareston For Breast Cancer
9 June 1997
UK Industry Code Of Practice In 1996
24 March 1997
IFPMA Reports On Marketing Code Breaches
24 June 1996
EMEA 1995-95: A Crucial Period of Transition
25 March 1996
EU CPMP Plenary Meeting In February
26 February 1996
EMEA Approves Roche's CellCept
26 February 1996
Isepalline Launched In First European Market
30 October 1995
Toremifene Launched In Japan
17 July 1995
Schering-Plough Is "Right-Sized And Flexible"
3 July 1995
Six New Ingredients For Japan's NHI List
19 June 1995
Fareston US Marketing Agreement
10 April 1995
CPAC Approves Six Drugs In Japan
3 April 1995
BREAST CANCER US RESEARCH UPDATE
26 April 1993
Showing 1-35 of 35 articles
- 1
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
